10-Q: Inspire Veterinary Partners Q3: Net Loss Narrows, Revenue Dips

Inspire Veterinary Partners reported a reduced net loss for Q3 2025, despite a slight decrease in total revenue, as it continues its acquisition strategy and manages high-interest debt.

Summary

• Net loss for the nine months ended September 30, 2025, decreased to $7,975,878 from $10,297,539 in the prior year, a 23% reduction.
• Net loss for the three months ended September 30, 2025, decreased to $2,526,273 from $3,489,326 in the prior year, a 28% reduction.
• Total revenue for the nine months ended September 30, 2025, decreased by 8% to $12,238,875 from $13,270,973.
• Total revenue for the three months ended September 30, 2025, increased by 7% to $4,316,132 from $4,049,025.
• Service revenue for the nine months decreased by 7% to $9,074,965, while product revenue decreased by 11% to $3,163,910.
• Service revenue for the three months increased by 6% to $3,138,670, and product revenue increased by 9% to $1,177,462.
• The company acquired DeBary Animal Clinic on June 4, 2025, for approximately $1,942,500 ($1,850,000 cash, $92,500 Class A common stock).
• Sold Kauai Veterinary Clinic (KVC) on September 20, 2024, for $2.0 million in assumed notes payable, resulting in a gain of $467,049 in 2024.
• Accumulated deficit as of September 30, 2025, was $44,326,158, and negative working capital was $5,894,301.
• Cash used in operating activities for the nine months ended September 30, 2025, was $3,555,276.
• The company raised approximately $6 million through the issuance of Series B convertible preferred stock and warrants in Q3 2025.
• Entered into a Common Stock Purchase Agreement with Seven Knots, LLC, for up to $50 million in Class A common stock, with no shares sold in Q3 2025.
• Issued two promissory notes to Target Capital LLC in June 2025, totaling $1,250,000 principal ($1,000,000 purchase price after OID).
• Entered into two Merchant Cash Advance Agreements in October 2025 for gross proceeds of $525,000 and $1,050,000, respectively.
• Issued Senior Convertible Promissory Notes in November 2025 for $357,142.86 principal ($250,000 purchase price after OID).

Sentiment

Score: 3

Explanation: While the net loss decreased and some revenue metrics improved in the quarter, the company continues to face significant financial challenges, including a substantial accumulated deficit, negative working capital, and reliance on high-interest financing, raising substantial doubt about its ability to continue as a going concern. The recent capital raises are crucial but highlight ongoing liquidity needs.

Positives

• Reduced net loss by 23% for the nine months and 28% for the three months ended September 30, 2025, compared to the prior year.
• Increased total revenue by 7% for the three months ended September 30, 2025, driven by higher service and product revenue per visit.
• Successfully raised approximately $6 million through the issuance of Series B convertible preferred stock and warrants in Q3 2025.
• Nasdaq notified the company on August 26, 2025, that it complies with the minimum stockholders' equity requirement, resolving a previous non-compliance notice from April 10, 2025.
• Interest expense decreased significantly by 51% for the nine months and 55% for the three months ended September 30, 2025, primarily due to a decrease in high-interest financing arrangements.
• Acquired DeBary Animal Clinic in June 2025, expanding its network to 14 clinics in 9 states.

Negatives

• Incurred recurring losses and had an accumulated deficit of $44,326,158 and negative working capital of $5,894,301 as of September 30, 2025.
• Total revenue for the nine months ended September 30, 2025, decreased by 8% compared to the prior year.
• Cash used in operating activities for the nine months ended September 30, 2025, was $3,555,276.
• Relies on high-interest merchant cash advance agreements for working capital, with effective interest rates as high as 42% (May 2025 amendment).
• The company's continuation as a going concern is contingent upon obtaining additional financing and generating revenue and cash flow.
• Adjusted Clinics EBITDA decreased significantly to $176,410 for the three months ended September 30, 2025, from $560,926 in the prior year, and to $463,056 for the nine months ended September 30, 2025, from $723,902 in the prior year.

Risks

• Going Concern: The company has incurred recurring losses and has an accumulated deficit of $44,326,158 and negative working capital of $5,894,301, raising substantial doubt about its ability to continue as a going concern for the next twelve months.
• Financing Risk: Continuation as a going concern is contingent upon obtaining additional financing (debt or equity) and generating sufficient revenue and cash flow, with no guarantee of successful funding on acceptable terms.
• Dilution: If additional capital is raised through equity offerings, the ownership interest of existing stockholders will be diluted.
• Debt Covenants: Raising additional capital through debt financing may subject the company to covenants limiting its ability to incur additional debt, make capital expenditures, or declare dividends.
• Acquisition Integration Risks: Risks to the ability to swiftly acquire and integrate new hospitals include national staffing shortages of veterinarians and technicians, costs and time associated with finding suitable targets and performing due diligence, and difficulties in achieving growth targets post-purchase.
• Post-Purchase Pressures: Rising talent acquisition and staffing costs, in addition to challenges in achieving productivity and average patient charges necessary for growth and profitability.
• Interest Rate Risk: Exposure to fluctuations in interest rates on floating-rate credit facilities, which could lead to more expensive loans and negatively impact valuation and profitability of acquired hospitals.
• Inflation Risk: If costs become subject to significant inflationary pressures, the company may not be able to fully offset higher costs through price increases, harming business, financial condition, and operating results.
• Conversion Price Adjustment: Warrants and convertible notes have provisions for conversion price adjustments upon lower-priced securities issuances or certain triggering events, potentially leading to greater dilution.
• Default Provisions: Convertible notes and promissory notes contain default provisions that could accelerate repayment at a premium (e.g., 150% or 120% of outstanding amounts) and increase interest rates (e.g., to 24% per annum).
• Asset Disposal Restrictions: While certain notes remain outstanding, the company may not, without lenders' written consent, sell, lease, or otherwise dispose of any significant portion of its assets except in the ordinary course of business.

Future Outlook

The company intends to continue expanding its offerings to include equine care, emergency and specialty services, more complex surgeries, holistic care, and comprehensive diagnostics. Growth strategies include seeking multi-unit practices with regional presence to increase the pace of growth and provide internal benefits like case referrals and career pathing. Management believes actions presently being taken to obtain additional funding provide the opportunity for the company to continue as a going concern, though there is no guarantee of success.

Management Comments

• "Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern."
• "The Company believes the breakdown of gross revenue into service revenue and product revenue categories produces meaningful measures to Company management and the Company’s investors in light of the Company’s objective to protect the service channel and derive the majority of its revenue from services and expertise which are not capable of disruption from other channels."
• "The Company views products such as parasite controls, veterinary nutrition products and additives as important, but the Company does not rely on product revenue to account for more than 20% to 30% of gross revenue."

Industry Context

The company operates in the veterinary services industry, specializing in small animal general practice hospitals, with recent expansion into equine care and plans for emergency and specialty services. It aims to match the industry target metric of 70% to 80% of gross revenue from services, which are less susceptible to disruption from non-veterinary channels. The industry faces national staffing shortages of veterinarians and technicians, which the company identifies as a risk to its acquisition and integration strategy. Advancements in veterinary care, such as anesthetic protocols, pain management, and fear-free medicine, are noted as positive developments for patient outcomes and life expectancy.

Comparison to Industry Standards

• The company aims to achieve an industry target metric of 70% to 80% of gross revenue derived from services (examination fees, diagnostics, surgery, etc.), which it believes are less susceptible to disruption from non-veterinary channels.
• It uses metrics like Revenue Per Patient Per day (RPP) and Average Patient Charge (APC) to analyze the comprehensive nature of diagnostics and services, which are referred to as "quality medicine metrics" within the veterinary service industry.
• The company's valuation analysis of acquired client lists uses a "Veterinary Services industry rate" of 74% for customer retention.

Corporate Governance

Related Party Transactions

• Blue Heron Consulting (BHC): Charles Stith Keiser (director) is COO, and his father, Dr. Charles Chuck Keiser, is Chief Visionary Officer. The company incurred $35,000 in expenses for BHC during Q3 2025 and $94,043 for the nine months ended September 30, 2025.
• Sale of KVC: Sold to Kauai RE Holdings LLC. Gregory Armstrong (shareholder) is a member of Kauai RE. Charles Keiser, DVM (father of board member Charles Stith Keiser), is also a member of Kauai RE.
• Guarantees on Loans: Kimball Carr (CEO & President) guarantees borrowings under the MLOCA and FSB commercial loans. Charles Stith Keiser (Board Member) also guarantees FSB commercial loans.

Stakeholder Impact

• Shareholders: Potential for significant dilution from ongoing equity raises and convertible debt. The company's going concern risk poses a material threat to shareholder value. Nasdaq compliance is a positive for listing status.
• Employees: Continued employment of former owners is a contingency for holdback payments in acquisitions (Valley Vet, DeBary Animal Clinic). National staffing shortages for veterinarians and technicians are a risk.
• Customers (Pet Owners): Expansion into new services (equine, emergency, specialty) and focus on comprehensive care aim to improve service offerings.
• Creditors: High-interest debt and reliance on merchant cash advances indicate elevated credit risk. Loan guarantees by CEO and a board member provide some security. Default provisions in convertible notes and promissory notes could lead to accelerated repayment at a premium.

Next Steps

• Continue to seek additional funding through debt or equity financing during the next twelve months.
• Expand offerings to include emergency care, mixed animal care (bovine, additional equine), and more complex surgeries, holistic care, and comprehensive diagnostics.
• Seek multi-unit practices with regional presence to facilitate growth and provide internal benefits.
• Complete valuation procedures and obtain additional information for the DeBary Animal Clinic acquisition purchase price allocation within one year from the acquisition date (June 4, 2025).
• Make monthly payments on OID Notes to Diagonal Lending and Boot Capital starting November 30, 2025.
• Make weekly payments on Merchant Cash Advance Agreements starting October 17, 2025, and October 31, 2025.
• Repay Senior Convertible Promissory Notes in full from any Qualified Financing or by maturity on August 5, 2026.

Key Dates

Recommendation

The company faces substantial doubt about its ability to continue as a going concern due to recurring losses, a significant accumulated deficit, and negative working capital. While net loss has decreased and some revenue metrics show quarterly improvement, the overall financial health remains precarious. The reliance on high-interest merchant cash advances and continuous equity/debt raises, which lead to significant dilution and high financing costs, indicates a challenging liquidity position. The decrease in Adjusted Clinics EBITDA further highlights operational struggles. The inherent risks associated with its aggressive acquisition strategy in a competitive, labor-constrained market, coupled with the potential for further dilution and default penalties, make this a high-risk investment with significant downside potential.

Keywords

Veterinary services, animal hospitals, pet care, acquisitions, SEC filing, 10-Q, financial results, net loss, revenue, debt, capital raise, Nasdaq, going concern, IVP